SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is generating intense community buzz as the stock holds steady near the $5 level amid heavy short interest and anticipation surrounding upcoming data updates at the AACR conference. Long-term shareholders remain focused on the potential for clinical trial readouts to trigger a significant revaluation, while actively debating the impact of upcoming options expiration and the feasibility of an early trial halt based on therapeutic efficacy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing significant volatility driven by intense retail interest and a high-stakes battle between long-term investors and short sellers amid speculation surrounding imminent regulatory news and global expansion efforts. The community is actively tracking option hedging, potential short squeeze dynamics, and the impact of institutional accumulation on the stock's price action.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing significant market interest following news that Greenland approved the transfer of a majority stake in the Tanbreez project, solidifying the company's control over a massive rare earth deposit. Community members are actively debating the potential for a short squeeze and long-term revaluation, with many highlighting the stock's strategic importance for Western supply chains and national security.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is experiencing significant market interest driven by an upsized capital raise of over 900 million dollars, which investors are viewing as a strategic growth catalyst to accelerate its transition into AI and high-performance computing data centers. The community is actively discussing the company's strong institutional backing and long-term infrastructure potential, with many traders closely monitoring the stock's ability to maintain upward momentum as it navigates near-term volatility and institutional share dilution.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is generating significant buzz as investors weigh its robust hyperscaler contract pipeline against recent sector-wide volatility and geopolitical headwinds. The community is actively debating the company's valuation gap compared to its peers, with many seeing the current price action as a potential accumulation zone while others express frustration over institutional selling patterns.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is trending as investors rally around reports of a pending U.S. executive order aimed at advancing ibogaine research for veteran mental health care. The community is actively debating the potential for a short squeeze, fueled by the company's low float and strong volume, while some skeptics express caution regarding the firm's history of dilution and trial timelines.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in retail interest driven by anticipation surrounding its prostate cancer therapy's clinical data and potential BLA filing. Community sentiment is mixed, with long-term investors highlighting the company's valuation gap relative to its pipeline potential, while skeptics focus on the lack of near-term catalysts and management's past performance.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the stock experiences intense volatility following the appointment of a new CEO, a $1 billion capital raise, and expanded partnership plans with Uber. Despite these strategic moves, investors are actively debating the company's long-term viability, citing persistent dilution concerns and a challenging path to profitability.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant investor attention fueled by strategic partnerships with Nvidia, specifically regarding quantum computing AI tools and hardware integration. Community sentiment remains highly bullish, with many traders drawing parallels to other quantum sector leaders and anticipating a potential price re-rating as the company expands its space and defense contracts.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense volatility driven by a massive, sentiment-fueled short squeeze that has detached the stock price from its underlying fundamentals. While retail traders and some hedge funds are actively debating the sustainability of this rally versus a looming structural collapse, the conversation is dominated by intense speculation regarding potential share dilution, institutional exit strategies, and whether the momentum can persist toward historic highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Sight Sciences (NASDAQ:SGHT) CFO Sells 7,231 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CFO James Rodberg sold 7,231 shares of Sight Sciences stock in a transaction on Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $25,670.05. Following the transaction, the chief financial officer owned...

Sight Sciences (NASDAQ:SGHT) Insider Sells $48,851.55 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 13,761 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $3.55, for...

Sight Sciences (NASDAQ:SGHT) CFO James Rodberg Sells 7,231 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CFO James Rodberg sold 7,231 shares of the company's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average...

Sight Sciences (NASDAQ:SGHT) CEO Sells $108,202.80 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 29,244 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $3.70, for a...

Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) EVP Brenton Taylor sold 2,869 shares of Sight Sciences stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $10,615.30. Following the completion of the transaction, the executive...

Sight Sciences (NASDAQ:SGHT) CEO Sells 29,244 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 29,244 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average...

Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 8,168 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 8,168 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average...

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a ho...

Sight Sciences (NASDAQ:SGHT) Price Target Cut to $11.00 by Analysts at UBS Group

UBS Group cut their price target on Sight Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a report on Friday...

Sight Sciences (NASDAQ:SGHT) Price Target Lowered to $6.50 at Citigroup

Citigroup decreased their price objective on shares of Sight Sciences from $9.10 to $6.50 and set a "neutral" rating for the company in a research note on Friday...

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Current Price	$4.09
Prev Close	$3.83
Open	$3.90
Dividend Yield	0.00%
50-Day Moving Average	$4.43
Beta	1.98
Avg. Volume	442,139.51
PE Ratio	-5.17

52-Week High	$9.24
52-Week Low	$2.51
Market Capitalization	$206.84M
EPS (Annual)	-$0.7369
Price to Book	3.20
Revenue Per Employee	$415,930.11

SGHT
Sight Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGHT News

SGHTSight Sciences Inc